New hope for advanced colon cancer patients in late-stage trial

NCT ID NCT07549412

Recruiting now Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 30, 2026 · Last updated May 25, 2026 · Updated 4 times

Summary

This study tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has not responded to prior therapies. About 1,020 adults who have already tried several standard treatments will participate. The goal is to see if the new drug helps people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

GenesisCare North Shore (Oncology)
RECRUITING

St Leonards, New South Wales, 2065, Australia
Icon Cancer Centre Chermside
RECRUITING

Chermside, Queensland, 4032, Australia
Profound Research LLC at Cancer and Leukemia Center
RECRUITING

Troy, Michigan, 48098, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC COLORECTAL CANCER